U.S. Markets close in 2 hrs 15 mins
  • S&P 500

    4,222.43
    +55.98 (+1.34%)
     
  • Dow 30

    33,888.19
    +598.11 (+1.80%)
     
  • Nasdaq

    14,138.94
    +108.57 (+0.77%)
     
  • Russell 2000

    2,284.01
    +46.26 (+2.07%)
     
  • Crude Oil

    73.90
    +2.26 (+3.15%)
     
  • Gold

    1,783.10
    +14.10 (+0.80%)
     
  • Silver

    26.05
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1920
    +0.0055 (+0.4649%)
     
  • 10-Yr Bond

    1.4800
    +0.0300 (+2.07%)
     
  • Vix

    18.36
    -2.34 (-11.30%)
     
  • GBP/USD

    1.3932
    +0.0123 (+0.8931%)
     
  • USD/JPY

    110.2400
    +0.0900 (+0.0817%)
     
  • BTC-USD

    32,443.50
    -2,259.21 (-6.51%)
     
  • CMC Crypto 200

    789.16
    -61.19 (-7.20%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

CMD or ABMD: Which Is the Better Value Stock Right Now?

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors interested in Medical - Instruments stocks are likely familiar with Cantel Medical (CMD) and Abiomed (ABMD). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Cantel Medical has a Zacks Rank of #2 (Buy), while Abiomed has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that CMD likely has seen a stronger improvement to its earnings outlook than ABMD has recently. But this is only part of the picture for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

CMD currently has a forward P/E ratio of 29.35, while ABMD has a forward P/E of 61.70. We also note that CMD has a PEG ratio of 1.54. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ABMD currently has a PEG ratio of 3.01.

Another notable valuation metric for CMD is its P/B ratio of 4.09. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, ABMD has a P/B of 10.62.

These metrics, and several others, help CMD earn a Value grade of B, while ABMD has been given a Value grade of D.

CMD stands above ABMD thanks to its solid earnings outlook, and based on these valuation figures, we also feel that CMD is the superior value option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.